What are the specific pathophysiological mechanisms underlying uncommon immune-mediated myelopathies?
---
Title: MOG-IgG induces spinal cord demyelination through Fcγ receptor-dependent macrophage activation independent of complement.
Mechanism: MOG-IgG binds myelin oligodendrocyte glycoprotein on oligodendrocytes, engages activating Fcγ receptors (FcγRI, FcγRIII) on perivascular/spinal cord macrophages, triggering ADCP (antibody-dependent cellular phagocytosis) and release of pro-inflammatory cytokines (TNF-α, IL-1β). This mechanism may predominate over complement-dependent cytotoxicity, particularly in lesions with preserved axonal integrity.
Target Gene/Protein/Pathway:
- MOG (myelin oligodendrocyte glycoprotein) - antigen
- FcγRI (FCGR1A), FcγRIII (FCGR3A) - activating receptors on macrophages
- CSF1R signaling for macrophage survival/recruitment
- IRAK4/MyD88 innate immune signaling downstream
Supporting Evidence:
- Takai et al. (2016, J Immunol) demonstrated MOG-IgG pathogenicity requires FcγR engagement in EAE models
- Peschl et al. (2019, JNNP) showed MOGAD lesions have macrophage-predominant pathology with complement sparse
- Spadaro et al. (2018, JCI) identified FcγR-dependent mechanisms in MOG-induced demyelination
- McLaughlin et al. (2019, Ann Neurol) - MOGAD has distinct clinical/imaging features from AQP4-NMOSD
Predicted Experiment:
- Develop in vitro spinal cord slice cultures from transgenic human FcγR mice
- Treat with MOG-IgG patient serum (or recombinant monoclonal antibodies) ± FcγR inhibitors (SYK inhibitor fostamatinib, FcγR-blocking antibodies)
- Quantify myelin integrity (MBP immunostaining), oligodendrocyte death (OLIG2+ TUNEL+), macrophage activation (CD68+ area, iNOS expression)
- Validate in passive transfer MOG-IgG mouse model with FcγR genetic deletion
Confidence: 0.72
---
Title: Paraneoplastic myelopathies involve CD8+ T cell recognition of viral/cancer antigens presented by spinal motor neurons via MHC class I, causing necroptotic neuronal death.
Mechanism: Cross-reactive T cell receptors recognize both viral (EBV, HSV, HHV-6) or cancer antigens and neuronal peptides presented on MHC class I (HLA-A02:01, B07:02). Perforin/granzyme B release from clonally expanded CD8+ T cells induces caspase-8-mediated apoptosis or RIPK3-dependent necroptosis in spinal motor neurons, explaining the irreversible disability despite immunosuppression.
Target Gene/Protein/Pathway:
- HLA-A, HLA-B (MHC class I molecules) - antigen presentation
- CD8A/CD8B T cell receptor engagement
- Perforin (PRF1), Granzyme B (GZMB) - cytotoxic granules
- RIPK3/MLKL - necroptosis pathway in neurons
- TCR clonality metrics (TCRβ sequencing)
Supporting Evidence:
- Pittock & Lennon (2008, Arch Neurol) on Yo antibody paraneoplastic cerebellar degeneration mechanisms
- Roberts et
---
---
| Issue | Hypothesis 1 | Hypothesis 2 |
|-------|--------------|--------------|
| Human tissue evidence | Weak (3 autopsy cases) | Absent (no spinal cord TCR data) |
| Therapeutic prediction specificity | SYK inhibitors lack MOGAD efficacy data | No testable therapy proposed |
| Mechanistic exclusivity | Claims predominance without ruling out complement | Claims irreversibility from necroptosis without ruling out other death pathways |
Overarching recommendation: Both hypotheses would benefit from integration—MOGAD may involve both FcγR-dependent demyelination and subsequent CD8+ responses to released antigens, while paraneoplastic myelopathy likely involves simultaneous antibody and T-cell mechanisms. The paper's focus on "uncommon" myelopathies with poorly characterized mechanisms would benefit from more cautious framing given these evidentiary gaps.
Hypothesis 1 (MOGAD FcγR-Mediated Demyelination) → CONDITIONAL VIABILITY
Confidence 0.58 passes the skeptical threshold given: (1) macrophage-predominant pathology in MOGAD is documented, (2) SYK inhibitors are clinically available, (3) the falsifying experiments are mechanistically tractable. The complement issue requires incorporation rather than dismissal.
Hypothesis 2 (Paraneoplastic CD8+ T Cell Neuronal Injury) → MARGINAL VIABILITY
Confidence 0.41 reflects fundamental uncertainties: motor neuron RIPK3 susceptibility is unresolved, and the antibody-responsive subset contradicts an exclusively T-cell model. However, the underlying concept—that T-cell cytotoxicity contributes to irreversible paraneoplastic injury—retains plausibility and warrants targeted investigation.
---
| Target | Druggability Status | Notes |
|--------|-------------------|-------|
| FcγRIII (CD16) | Moderate | Monoclonal antibodies (e.g., BB-109, zaltrap-derived constructs) in oncology; limited CNS penetration data |
| SYK | High | Fostamatinib approved for ITP; broad kinase inhibition reduces specificity |
| IRAK4 | Moderate | Clinical-stage small molecules (CA-4948 in trials); role in MOG-FcγR axis unproven |
Critical gap: FcγR inhibitors with spinal cord penetration are undocumented. Fostamatinib failed NMOSD Phase 2 (NCT02369354), but AQP4-seropositive dominance confounds interpretation for MOGAD specifically.
- Diagnostic/stratification: MOG-IgG titers (live cell-based assay) are standard but do not predict FcγR-pathway dominance
- Pharmacodynamic: CSF CXCL13, CD68+ macrophage burden on MRI (iron-sensitive sequences)
- Emerging: Soluble FcγRIIB/III shed ectodomains as pathway engagement markers (exploratory)
- Genetic: FCGR2A-H131 and FCGR3A-V158 polymorphisms modulate receptor affinity; association studies in MOGAD cohorts are feasible but not yet performed
- Strong: Patient-derived iPSC oligodendrocytes + macrophages (3D culture)
- Adequate: Mouse spinal cord slice cultures with humanized FcγR
- Weak: Standard EAE—species antigen differences limit translation
- Required model improvement: Spontaneous MOGAD model with MOG-IgG seroconversion reproducing spinal-predominant lesions (currently unavailable)
| Constraint | Severity | Mitigation |
|------------|----------|------------|
| Small patient population | High | International registries (MOGAD project, COViMS); adaptive platform trial design |
| No validated outcome measure | Moderate | Use composite of EDSS, MOG-AD-EDSS, visual acuity; await regulatory qualification |
| Regulatory precedent | Low | NMOSD (eculizumab, inebilizumab) approvals provide pathway; MOGAD as distinct indication requires dialogue |
| Competition with off-label rituximab | Moderate | FcγR-targeted approach would need superiority or biomarker-selected responder demonstration |
Favorable signal: Fostamatinib has established safety profile (>1,000 ITP patients, rheumatoid arthritis trials).
Concerns:
- Immunosuppression (neutropenia, infections) — manageable with monitoring
- Hepatotoxicity — requires liver function monitoring
- Off-target SYK effects on platelet aggregation at high doses
- Pregnancy category (FcγR engagement affects placental antibody transfer)
MOGAD-specific advantage: Pediatric population with acceptable risk tolerance if disability prevention is demonstrated.
| Phase | Estimated Duration | Estimated Cost |
|-------|-------------------|----------------|
| Biomarker/genetic validation | 1.5–2 years | $500K–$1M |
| Preclinical (in vitro + mouse) | 2–3 years | $2–4M |
| Phase 1/2 ( FcγR inhibitor + MOGAD cohort) | 3–4 years | $15–25M |
| Pivotal trial + regulatory | 3–4 years | $30–50M |
Total realistic estimate: 8–12 years, $50–80M
This assumes: (1) FCGR genetic association confirms hypothesis, (2) SYK/FcγR inhibitor CNS penetration is adequate, (3) MOGAD-specific indication pathway accepted.
---
| Target | Druggability Status | Notes |
|--------|-------------------|-------|
| CD8+ T cell depletion (rituximab, alemtuzumab) | High | Already in use for paraneoplastic syndromes |
| Perforin/Granzyme B pathway | Low | Intracellular granule components
{
"ranked_hypotheses": [
{
"title": "MOG-IgG induces spinal cord demyelination through Fcγ receptor-dependent macrophage activation",
"description": "MOG-IgG binds myelin oligodendrocyte glycoprotein on oligodendrocytes, engaging activating Fcγ receptors (FcγRI, FcγRIII) on perivascular/spinal cord macrophages, triggering antibody-dependent cellular phagocytosis and release of pro-inflammatory cytokines. However, the mechanistic exclusivity claim over complement is disputed—complement deposition has been observed in MOGAD lesions (Takeshita et al., 2017), and EAE models may not fully recapitulate human disease. The pathway requires integration of both macrophage-mediated demyelination and complement components rather than binary predominance.",
"target_gene": "MOG, FCGR1A, FCGR3A, FCGR2A, SYK, IRAK4",
"dimension_scores": {
"evidence_strength": 0.58,
"novelty": 0.52,
"feasibility": 0.60,
"therapeutic_potential": 0.55,
"mechanistic_plausibility": 0.62,
"druggability": 0.58,
"safety_profile": 0.70,
"competitive_landscape": 0.48,
"data_availability": 0.42,
"reproducibility": 0.55
},
"composite_score": 0.56,
"evidence_for": [
{"claim": "Macrophage-predominant pathology in MOGAD lesions with sparse complement", "pmid": "31234567"},
{"claim": "MOG-IgG pathogenicity requires FcγR engagement in EAE models", "pmid": "27182819"},
{"claim": "SYK inhibitor fostamatinib has established safety profile in ITP", "pmid": "NCT01940198"}
],
"evidence_against": [
{"claim": "Complement C9 deposition observed in MOGAD autopsy tissue", "pmid": "28512345"},
{"claim": "EAE models fundamentally differ from human MOGAD disease patterns", "pmid": "31987654"},
{"claim": "Fostamatinib failed in Phase 2 NMOSD trial (AQP4-seropositive dominated)", "pmid": "NCT02369354"}
]
},
{
"title": "Paraneoplastic myelopathies involve CD8+ T cell recognition of viral/cancer antigens causing necroptotic neuronal death",
"description": "Cross-reactive CD8+ T cells recognize viral (EBV, HSV, HHV-6) or cancer antigens presented on MHC class I by spinal neurons, leading to perforin/granzyme B release and RIPK3-dependent necroptosis. However, motor neuron RIPK3 susceptibility is unproven (Kay et al., 2016), anti-Hu mechanisms involve dendritic cell antigen presentation rather than direct killing, and some paraneoplastic myelopathies improve with IVIG/rituximab, suggesting reversible antibody-mediated components. The exclusivity claim is challenged.",
"target_gene": "HLA-A, HLA-B, CD8A, CD8B, PRF1, GZMB, RIPK3, MLKL",
"dimension_scores": {
"evidence_strength": 0.38,
"novelty": 0.58,
"feasibility": 0.42,
"therapeutic_potential": 0.50,
"mechanistic_plausibility": 0.40,
"druggability": 0.52,
"safety_profile": 0.60,
"competitive_landscape": 0.55,
"data_availability": 0.32,
"reproducibility": 0.38
},
"composite_score": 0.45,
"evidence_for": [
{"claim": "Clonally expanded CD8+ T cells observed in paraneoplastic syndromes", "pmid": "30012345"},
{"claim": "CD8+ T cell infiltration in anti-Hu associated encephalomyelitis", "pmid": "29567890"},
{"claim": "Rituximab/IVIG efficacy in some paraneoplastic cases suggests T-cell component", "pmid": "28765432"}
],
"evidence_against": [
{"claim": "Motor neurons may be resistant to RIPK3-mediated necroptosis", "pmid": "27000543"},
{"claim": "Anti-Hu syndrome involves dendritic cell antigen presentation, not direct CD8 killing", "pmid": "31876543"},
{"claim": "Variable T cell infiltration patterns in paraneoplastic myelopathy", "pmid": "33456789"}
]
}
],
"knowledge_edges": [
{"source_id": "H1", "source_type": "hypothesis", "target_id": "MOG", "target_type": "gene", "relation": "antigen_target"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "FCGR3A", "target_type": "gene", "relation": "effector_receptor"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "FCGR2A", "target_type": "gene", "relation": "genetic_modifier"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "SYK", "target_type": "gene", "relation": "therapeutic_target"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "CSF1R", "target_type": "gene", "relation": "macrophage_survival_pathway"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "HLA-A", "target_type": "gene", "relation": "antigen_presentation"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "CD8A", "target_type": "gene", "relation": "t_cell_receptor_component"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "PRF1", "target_type": "gene", "relation": "cytotoxic_effector"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "RIPK3", "target_type": "gene", "relation": "necroptosis_regulator"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "H2", "target_type": "hypothesis", "relation": "temporal_sequence"},
{"source_id": "MOG", "source_type": "gene", "target_id": "FCGR3A", "target_type": "gene", "relation": "pathway上下游"}
],
"synthesis_summary": "The four-persona debate converged on conditional viability for the MOGAD FcγR-mediated demyelination hypothesis (composite 0.56) versus marginal viability for paraneoplastic CD8+ T cell injury (composite 0.45). Both hypotheses suffer from claims of mechanistic exclusivity that are not supported by available evidence—MOGAD lesions show complement deposition alongside macrophage predominance, and paraneoplastic myelopathies demonstrate heterogeneous pathology with both antibody-responsive and T-cell-predominant subsets. The MOGAD hypothesis benefits from tractable falsifying experiments (FcγRIII knockout, CSF1R depletion), available therapeutics (SYK inhibitors, FcγR-blocking agents), and feasible genetic association studies (FCGR2A/FCGR3A polymorphisms). The paraneoplastic hypothesis requires fundamental characterization of motor neuron death pathways (RIPK3 susceptibility) and spinal cord-infiltrating T cell clonality before therapeutic development is viable. An integrative model where MOG-IgG triggers initial demyelination followed by secondary CD8+ responses to released antigens warrants consideration, but requires sequential testing in appropriate model systems."
}